Skip to main content

Milk Fat Globule Membrane-Enriched Formula and Cognition Among Formula-Fed Infants: A Randomized Clinical Trial

In brief

Milk fat globule membrane formula cut cognitive-delay risk by more than half

In a randomized trial, 4.8% of infants receiving enriched formula had delayed cognition at 12 months, compared with 11.5% on standard formula. Average cognitive scores did not improve, and a small language-score advantage at 24 months was no longer significant after accounting for caregiver education. The reduction in cognitive delay needs further investigation before its practical significance is clear.

Journal
JAMA network open (Q1)
Published
2 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jacqueline F Gould, Robert A Gibson, Lisa N Yelland, John Colombo, Andrew J McPhee, Jana Bednarz, et al.
PMID
43056116
DOI
10.1001/jamanetworkopen.2026.44537

Why clinicians should know about it

  • Picked for Pediatrics and Child Health (top studies of the week, 22 November 2026): Infant formula nutrition trial evaluates cognitive development and growth

Abstract

IMPORTANCE: The absence of milk fat globule membrane (MFGM) in infant formula may contribute to the differences between breastfed and formula-fed infants. OBJECTIVE: To test whether MFGM-enriched infant formula benefits cognitive development of exclusively formula-fed infants. DESIGN, SETTING, AND PARTICIPANTS: This clinician-blinded, researcher-blinded, and participant-blinded randomized clinical trial of exclusively formula-fed infants with a reference group (exclusively breastfed) included full-term singleton infants under 2 months of age, who were recruited from the community (May 2020 to April 2022). Follow-up was completed in June 2024 and analyses completed in September 2025. INTERVENTIONS: Randomized infants received either MFGM-enriched formula (treatment group: 0.55 g per 100.00 g of MFGM component phospholipid from MFGM Lipid 100 [New Zealand Milk Products, Fonterra Co-Operative Group Limited]) or standard formula (control group: no added MFGM, 0.29 g per 100.00 g of MFGM component phospholipid) from randomization to 12 months of age. MAIN OUTCOMES AND MEASURES: The Bayley Scales of Infant and Toddler Development, 4th Edition scales for cognitive, language, motor, emotional, and behavioral development, in which the mean (SD) score is 100 (15), with scores below 85 classified as delayed, were administered at ages 12 months and 24 months; the primary outcome was the 12-month cognitive score. Caregivers reported health, language, development, growth, safety, and tolerance. RESULTS: There were 416 randomized formula-fed infants (mean [SD] age, 36.6 [11.5] days; 209 males [50.2%]) and 204 reference group infants. Primary outcome data were available for 382 randomized infants (91.8%), including 193 (93.2%) of 207 in the treatment group and 189 (90.4%) of 209 in the control group. The mean (SD) 12-month cognitive scores in the treatment group (100.1 [11.9]) and control group (99.4 [14.1]) were not significant (adjusted mean difference, 0.68 [95% CI, -1.94 to 3.31]; P = .61). There was a significantly lower risk of delayed cognition (<85) at age 12 months in the treatment group compared with the control group (10.0 [4.8%] vs 24.1 [11.5%]; adjusted relative risk, 0.42 [95% CI, 0.20-0.90]; P = .03), and the mean (SD) language scores at age 24 months were higher in the treatment group compared with the control group (93.0 [16.3] vs 90.0 [16.6]; adjusted mean difference, 2.87 [95% CI, 0.10-5.65]; P = .04), although this difference was not statistically significant after controlling for caregiver educational level. Other secondary developmental outcomes, as well as growth and safety outcomes, were mostly not significant. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of MFGM-supplemented formula compared with standard formula among nonbreastfed infants, mean cognitive scores were not improved, although a reduction in the number of infants with cognitive delay is worthy of further investigation. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry identifier: ACTRN12620000552987.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.